These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38253622)

  • 1. Hydroxynorketamine, but not ketamine, acts via α7 nicotinic acetylcholine receptor to control presynaptic function and gene expression.
    Guhathakurta D; Petrušková A; Akdaş EY; Perelló-Amorós B; Frischknecht R; Anni D; Weiss EM; Walter M; Fejtová A
    Transl Psychiatry; 2024 Jan; 14(1):47. PubMed ID: 38253622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antidepressant-relevant concentrations of the ketamine metabolite (2
    Lumsden EW; Troppoli TA; Myers SJ; Zanos P; Aracava Y; Kehr J; Lovett J; Kim S; Wang FH; Schmidt S; Jenne CE; Yuan P; Morris PJ; Thomas CJ; Zarate CA; Moaddel R; Traynelis SF; Pereira EFR; Thompson SM; Albuquerque EX; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5160-5169. PubMed ID: 30796190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cAMP-dependent protein kinase signaling is required for (
    Riggs LM; Pereira EFR; Thompson SM; Gould TD
    J Neurophysiol; 2024 Jan; 131(1):64-74. PubMed ID: 38050689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
    Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
    Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (
    Zanos P; Highland JN; Stewart BW; Georgiou P; Jenne CE; Lovett J; Morris PJ; Thomas CJ; Moaddel R; Zarate CA; Gould TD
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6441-6450. PubMed ID: 30867285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism.
    Riggs LM; Aracava Y; Zanos P; Fischell J; Albuquerque EX; Pereira EFR; Thompson SM; Gould TD
    Neuropsychopharmacology; 2020 Jan; 45(2):426-436. PubMed ID: 31216563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine.
    Shaffer CL; Dutra JK; Tseng WC; Weber ML; Bogart LJ; Hales K; Pang J; Volfson D; Am Ende CW; Green ME; Buhl DL
    Neuropharmacology; 2019 Jul; 153():73-81. PubMed ID: 31015046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant actions of ketamine engage cell-specific translation via eIF4E.
    Aguilar-Valles A; De Gregorio D; Matta-Camacho E; Eslamizade MJ; Khlaifia A; Skaleka A; Lopez-Canul M; Torres-Berrio A; Bermudez S; Rurak GM; Simard S; Salmaso N; Gobbi G; Lacaille JC; Sonenberg N
    Nature; 2021 Feb; 590(7845):315-319. PubMed ID: 33328636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.
    Chou D; Peng HY; Lin TB; Lai CY; Hsieh MC; Wen YC; Lee AS; Wang HH; Yang PS; Chen GD; Ho YC
    Neuropharmacology; 2018 Sep; 139():1-12. PubMed ID: 29953886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
    Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
    Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxynorketamine Blocks
    Abbott JA; Popescu GK
    Mol Pharmacol; 2020 Sep; 98(3):203-210. PubMed ID: 32606205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors.
    Moaddel R; Abdrakhmanova G; Kozak J; Jozwiak K; Toll L; Jimenez L; Rosenberg A; Tran T; Xiao Y; Zarate CA; Wainer IW
    Eur J Pharmacol; 2013 Jan; 698(1-3):228-34. PubMed ID: 23183107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family of Structurally Related Bioconjugates Yields Antibodies with Differential Selectivity against Ketamine and 6-Hydroxynorketamine.
    Zheng Z; Kyzer JL; Worob A; Wenthur CJ
    ACS Chem Neurosci; 2021 Nov; 12(21):4113-4122. PubMed ID: 34652905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
    Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
    Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.
    Yokoyama R; Higuchi M; Tanabe W; Tsukada S; Naito M; Yamaguchi T; Chen L; Kasai A; Seiriki K; Nakazawa T; Nakagawa S; Hashimoto K; Hashimoto H; Ago Y
    Pharmacol Biochem Behav; 2020 Apr; 191():172876. PubMed ID: 32088360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine.
    Chen BK; Luna VM; LaGamma CT; Xu X; Deng SX; Suckow RF; Cooper TB; Shah A; Brachman RA; Mendez-David I; David DJ; Gardier AM; Landry DW; Denny CA
    Neuropsychopharmacology; 2020 Aug; 45(9):1545-1556. PubMed ID: 32417852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.
    Chou D
    Neuropharmacology; 2020 Jun; 170():108068. PubMed ID: 32222405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
    Zanos P; Highland JN; Liu X; Troppoli TA; Georgiou P; Lovett J; Morris PJ; Stewart BW; Thomas CJ; Thompson SM; Moaddel R; Gould TD
    Br J Pharmacol; 2019 Jul; 176(14):2573-2592. PubMed ID: 30941749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model.
    Ju L; Yang J; Zhu T; Liu P; Yang J
    BMC Psychiatry; 2022 Mar; 22(1):182. PubMed ID: 35291971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative chiral and achiral determination of ketamine and its metabolites by LC-MS/MS in human serum, urine and fecal samples.
    Hasan M; Hofstetter R; Fassauer GM; Link A; Siegmund W; Oswald S
    J Pharm Biomed Anal; 2017 May; 139():87-97. PubMed ID: 28279931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.